Clinical Trial

ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study

Study acronym: ELCIN
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with estrogen receptor positive (ER+)/human epidermal growth factor receptor-2 negative (HER2-) advanced/metastatic breast cancer who received no prior cyclin-dependent kinase targeting enzymes CDK4 and CDK6 inhibitor (CDK4/6i) in the metastatic setting.
Protocol Amendment History 1 change
notable Trial sites reduced: 34 -> 22 locations 2026-05-08
Trial Details
NCT Number NCT05596409
Lead Sponsor Stemline Therapeutics, Inc.
Conditions Metastatic Breast Cancer
Enrollment 61 participants
Start Date 2023-05-19
Primary Completion 2026-11 (estimated)
Study Completion 2027-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-07